Zobrazeno 1 - 10
of 385
pro vyhledávání: '"Nu Lin"'
Autor:
Cheng-Yu Chang, Fu-Mei Wu, Hsu-Nu Lin, Lun-Hui Ho, Jui Yuan Su, Ching-Chuan Liang, Shu-Hua Yang, Tzyy-Jen Huang, Pei-Fan Mu
Publikováno v:
JBI evidence implementation. 20(4)
The aim of this project was to promote for the family caregivers of stroke patients the resilience evidence translation care model in the community.Stroke is the main cause of disability among many patients with chronic diseases. Resilience helps fam
Publikováno v:
Archives of Pharmacal Research. 43:371-384
Sulforaphane is an isothiocyanate compound that has been derived from cruciferous vegetables. It was shown in numerous studies to be active against multiple cancer types including pancreatic, prostate, breast, lung, cervical, and colorectal cancers.
Autor:
Carlos Teodoro Vallejo, Nu Lin, Rachel A. Freedman, Julieta Leone, EP Winer, Jose Pablo Leone, Sara M. Tolaney, AO Zwenger, Bernardo Amadeo Leone
Publikováno v:
Cancer Research. 79:P6-19
Background: Male breast cancer (MaBC) is an uncommon disease, and population-based information regarding prognostic factors is limited. Most MaBC are hormone receptor (HR) positive, however, the association of tumor subtypes with overall survival (OS
Autor:
Pedro Exman, KE Economy, Nadine Tung, Heather A. Parsons, Erica L. Mayer, Beverly Moy, Wendy Y. Chen, AH Partridge, TS Freret, Nu Lin
Publikováno v:
Cancer Research. 79:P1-17
Background BCP is uncommon; however, the frequency is increasing due to trends in delayed childbearing. Studies have suggested that some systemic therapies, including doxorubicin and cyclophosphamide, can be delivered safely during pregnancy after th
Autor:
Pedro Exman, Elizabeth A. Mittendorf, FS Hodi, Deborah A. Dillon, Romualdo Barroso-Sousa, Neal I. Lindeman, N Wagle, Ian E. Krop, Svitlana Tyekucheva, Nu Lin, Sara M. Tolaney, Esha Jain, Ana C. Garrido-Castro, Laura E. MacConaill, Melissa E. Hughes, Renato Umeton, EP Winer, Janet Files, S Pernas-Simon, Brittany L. Bychkovsky, S Di Lascio
Publikováno v:
Cancer Research. 79:P5-12
Purpose: To date no biomarker has been identified that predicts response to ICI in mTNBC. This study aimed to explore if tumor genomic alterations correlate with efficacy of PD-1/PD-L1 inhibition in patients (pts) with mTNBC. Methods: Demographic, tr
Autor:
E. Le Rhun, Z Yang, Sara M. Tolaney, Yanyun Chen, Nu Lin, M Markel Bear, Carey K. Anders, Solmaz Sahebjam
Publikováno v:
Cancer Research. 79:P1-19
Background Abemaciclib is a selective CDK4 & 6 inhibitor approved to treat patients (pts) with HR+, HER2- advanced breast cancer (ABC) on a continuous dosing schedule as monotherapy or in combination with endocrine therapy.1,2,3 Clinical data demonst
Autor:
Ravi Murthy, Virginia F. Borges, Erika Hamilton, Elisavet Paplomata, S.A. Hurvitz, Sherene Loi, Vandana G. Abramson, Nu Lin, Luke Walker
Publikováno v:
Cancer Research. 79:OT2-07
This abstract was withdrawn by the authors. Citation Format: Paplomata E, Borges V, Loi S, Abramson V, Hamilton E, Hurvitz S, Lin N, Walker L, Murthy RK. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec
Autor:
Lindsey M. Crowley, N Kuhnly, G Gupta, EP Winer, Merrill, Rebecca A. Santiago, Elizabeth S. Frank, Nu Lin, Melissa E. Hughes
Publikováno v:
Cancer Research. 78:P4-10
Background: In contrast to early stage breast cancer, the quality of care for patients with metastatic breast cancer (MBC) has been relatively understudied, as have interventions to improve care in the real-world setting. Patients with MBC face a var
Autor:
Emily Schlosnagle, Laura S. Dominici, Faina Nakhlis, J Hirshfield-Bartek, Meredith M. Regan, Beth T. Harrison, AH Partridge, A Morikawa, Jennifer R. Bellon, Rachel A. Freedman, Nu Lin, Beth Overmoyer, EP Winer, DE Morganstern, Jiani Hu
Publikováno v:
Cancer Research. 78:P6-15
Background: Inflammatory breast cancer (IBC) is inoperable at presentation, thus neoadjuvant systemic therapy (NAS) is the primary treatment for this aggressive disease. Due to its rarity, patients (pts) with IBC are incorporated into NAS clinical tr
Autor:
Nu Lin
Publikováno v:
Cancer Research. 81:SP083-SP083
Over the past two decades, there have been tremendous advances in treatment options for patients with HER2+ metastatic breast cancer (MBC). Median overall survival (OS) in control arm of the pivotal trastuzumab + chemotherapy study (Slamon et al, NEJ